-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although dual antiplatelet therapy (DAPT) with aspirin combined with clopidogrel (ASA+CLO) can reduce the risk of early recurrence after mild ischemic stroke and high-risk transient ischemic attack (TIA)
Aspirin combined with clopidogrel (ASA+CLO) dual antiplatelet therapy (DAPT) transient ischemic attack (TIA)
A meta-analysis showed that DAPT of ASA+CLO, initiated mainly within 24 hours of stroke onset, significantly reduced the risk of recurrent ischemic stroke within 3 months of stroke onset, but significantly increased major bleeding within 1 month of stroke onset risk
Cilostazol Cilostazol plus aspirin (CLZ + ASA) Cilostazol plus clopidogrel (CLZ + CLO)
Researchers analyzed data from the csps website to test the hypothesis that starting cilostazol in the first few weeks is more effective and safer than aspirin or clopidogrel alone
- Of the 1879 patients, 498 were in the 8-14d group, 467 in the 15-28d group, and 914 in the 29-180d group
Long-term dual antiplatelet therapy with cilostazol initiated 15-180 days after stroke onset was more effective than 8-14 days after treatment initiation, and was more effective in preventing secondary stroke than monotherapy without increasing the risk of bleedingSource: Toyoda, Kazunori et al.
leave a message here
